arsenic trioxide + fuzuloparib

Arsenic trioxide + fuzuloparib is an investigational combination therapy being studied primarily for the treatment of platinum-resistant relapsed ovarian cancer. Arsenic trioxide is a small molecule chemotherapeutic agent that induces apoptosis and promotes differentiation, historically used as a first-line treatment for acute promyelocytic leukemia. Fuzuloparib is an orally administered small molecule inhibitor of poly(ADP-ribose) polymerase (PARP), which impairs DNA repair in tumor cells with homologous recombination deficiency, such as those with BRCA mutations. The rationale for combining these agents lies in their complementary mechanisms—arsenic trioxide’s cytotoxic effects and fuzuloparib’s targeted inhibition of DNA repair pathways—to potentially overcome resistance to platinum-based chemotherapy and enhance antitumor efficacy[1][2][6][9].